Browse studies

Find your next paid study

1,513 recruiting studies matching your filters

A Phase 1 Study to Investigate PF-08046033 in Participants With Advanced Solid Tumors

This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine i…

Non-Small-Cell LungEsophageal CancerCutaneous Melanoma

Estimated

~$10 – $7,500

PfizerNCT07519655

Older Breast Cancer Patients: Risk for Cognitive Decline. The Thinking and Living With Cancer (TLC) Study

The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition doma…

Cancer, BreastAge-related Cognitive DeclineCognitive Decline

Estimated

~$10 – $750

Georgetown UniversityNCT03451383

GLP-1 Longitudinal Outcomes in Weight Management

The goal of this observational study is to learn about the long-term effects of GLP-1RAs (Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound) in adolescents and …

Weight ManagementDisordered Eating Behaviors

Estimated

~$10 – $675

University of California, San FranciscoNCT07829016

Phase 1

A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors

The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to fur…

Advanced-stage Solid Tumors

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT07223125

Phase 1

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharma…

Gastric or Gastroesophageal Junction AdenocarcinomaPancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)+1 more

Estimated

~$10 – $8,750

Phanes TherapeuticsNCT05482893

Phase 2

A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophage…

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal AdenocarcinomaMetastatic Gastric CancerGastroesophageal Junction Cancer+1 more

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular …

Neovascular Age-Related Macular Degeneration

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT03683251

Observational

Single-Dose Stereotactic Radiosurgery (SDRT) as Definitive Non-Operative Treatment for Early-Stage Breast Cancer: A Prospective Single-Arm Pilot Trial With Bayesian Safety Monitoring (SOLIS / Protocol RAD 2024)

SOLIS is a prospective, single-arm, single-institution pilot trial evaluating single-fraction stereotactic radiotherapy (24 Gy to the planning target volume wi…

Breast CancerEarly-Stage Breast CarcinomaHormone Receptor-Positive Breast Cancer+1 more

Estimated

~$10 – $7,500

Renaissance Institute of Precision Oncology and RadiosurgeryNCT07844759

Phase 1

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and…

Breast CancerGastric CancerGastroesophageal-junction Cancer

Estimated

~$10 – $8,750

Iksuda Therapeutics Ltd.NCT05872295

A Multicenter, Prospective, Open-Label Registry Study of the Utilization of EsoGuard, on Samples Collected Using EsoCheck, in an At-Risk Population Undergoing Standard of Care Screening for, and Management of, Previously Undiagnosed Barrett's Esophagus and/or Esophageal Adenocarcinoma

This is a multicenter, prospective, observational study designed to capture a limited set of data consisting of diagnostic test results and clinical management…

Barrett EsophagusEsophageal AdenocarcinomaBarretts Esophagus With Dysplasia+1 more

Estimated

~$10 – $1,050

Lucid Diagnostics, Inc.NCT05965999

Observational

RSMI HEALS (Health Equity Advances Through Language Solutions) (AI)

The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/…

Breast CancerBreast Cancer Stage IIBreast Cancer Stage III

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06721065

Phase 2

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic le…

Acute Leukemia of Ambiguous LineageB Acute Lymphoblastic Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06317662